HC Wainwright Comments on Alumis’ Q1 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Alumis in a research note issued on Monday, March 30th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.70) for the quarter, up from their previous forecast of ($0.71). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.82) EPS and FY2026 earnings at ($2.89) EPS.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. The company had revenue of $1.93 million during the quarter, compared to analyst estimates of $2.75 million.

Several other research analysts have also weighed in on the company. Stifel Nicolaus assumed coverage on Alumis in a research report on Wednesday, February 25th. They set a “buy” rating and a $44.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Monday, December 29th. UBS Group reissued an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Leerink Partners boosted their target price on shares of Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, January 6th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Alumis in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Alumis has an average rating of “Moderate Buy” and an average price target of $38.60.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $22.73 on Wednesday. The stock has a 50 day moving average price of $26.34 and a 200 day moving average price of $14.85. The stock has a market capitalization of $2.89 billion, a PE ratio of -7.43 and a beta of -0.61. Alumis has a 52 week low of $2.76 and a 52 week high of $30.60.

Institutional Investors Weigh In On Alumis

Several hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after purchasing an additional 979 shares during the period. Russell Investments Group Ltd. raised its position in shares of Alumis by 320.9% in the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after purchasing an additional 4,894 shares during the period. CWM LLC lifted its stake in shares of Alumis by 1,028.7% during the 3rd quarter. CWM LLC now owns 10,384 shares of the company’s stock worth $41,000 after buying an additional 9,464 shares during the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Alumis by 199.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock worth $32,000 after buying an additional 7,165 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in shares of Alumis by 173.7% during the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after buying an additional 7,467 shares during the period.

Insiders Place Their Bets

In other Alumis news, major shareholder Foresite Labs, Llc acquired 411,764 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the purchase, the insider directly owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This represents a 7.78% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James B. Tananbaum acquired 411,764 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was acquired at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the transaction, the director owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. The trade was a 7.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 1,823,527 shares of company stock worth $30,999,959 over the last ninety days. 40.70% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright raised EPS estimates across Q1–Q4 and lifted FY2026/FY2027 outlooks (e.g., FY2026 from ($2.99) to ($2.89); Q1–Q4 tweaks), while maintaining a “Buy” rating and a $25 price target — this reduces projected losses and provides an analyst-backed upside case. HC Wainwright research coverage (summary)
• Positive Sentiment: Chardan Capital assigned a Buy rating, adding an additional institutional endorsement that can attract buyer interest. Alumis Earns Buy Rating from Chardan Capital
• Positive Sentiment: An Oppenheimer analyst is reported to expect the stock to rise, reinforcing bullish sentiment from multiple brokers and likely supporting demand. Oppenheimer bullish note
• Neutral Sentiment: General market coverage (CNN) lists ALMS among tracked stocks; broad news distribution can increase visibility but doesn’t by itself change fundamentals. CNN: Alumis Inc.
• Neutral Sentiment: A news piece with a contrary headline referencing a “pessimistic forecast” appeared, but the underlying broker actions (above) show upward revisions and Buy ratings — treat the conflicting headlines cautiously. HC Wainwright pessimistic forecast article

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.